SCHEMBL5887465

SCHEMBL5887465

COc1ccc(-c2[c]c3ccccc3cc2-c2ccccc2Cl)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.41
ABCB1 P08183 1/20 0.41
BCR P11274 1/20 0.41
PIK3CD O00329 2/20 0.38
BACE1 P56817 2/20 0.38
APP P05067 1/20 0.38
TEK Q02763 1/20 0.38
NPC1 O15118 4/20 0.38
RAB9A P51151 4/20 0.38
MAPK14 Q16539 2/20 0.37
PTPN1 P18031 1/20 0.37
KDM4E B2RXH2 1/20 0.37
MAPT P10636 1/20 0.37
CASP3 P42574 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887304 0.86 ABL1 (0.47) ABL1ABCB1BCRBACE1NPC1
SCHEMBL5887390 0.86 ABL1 (0.37) ABL1ABCB1BCRNPC1RAB9A
SCHEMBL5887216 0.85 AURKA (0.45) ABL1ABCB1BCRBACE1NPC1
SCHEMBL5887233 0.80 LTA4H (0.49) ABL1ABCB1BCRBACE1NPC1
SCHEMBL5887230 0.75 KDM4E (0.41) ABL1ABCB1BCRPIK3CDBACE1
SCHEMBL5887111 0.74 MAPT (0.48) NPC1RAB9AKDM4EMAPTCASP3
SCHEMBL5681041 0.73 ABL1 (0.60) ABL1ABCB1BCRBACE1APP
SCHEMBL11837610 0.73 CYP2A6 (0.50) BACE1NPC1RAB9AMAPK14KDM4E
SCHEMBL9844190 0.72 CYP2A6 (0.38) NPC1RAB9AMAPK14KDM4EL3MBTL1
SCHEMBL1234940 0.71 ALDH1A1 (0.37) L3MBTL1ALDH1A1TP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037931-B2 Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-02 US disclosed
US-20050026903-A1 CCK-1 receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-03 US disclosed
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders JONES TODD K (US) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders CCKAR, CCKBR, NPY1R ABL1 2767/4885ABCB1 859/4885BCR 1082/4885
US-20050026903-A1 CCK-1 receptor modulators CCKAR, CCKBR, GLP1R ABL1 2540/4885ABCB1 1319/4885BCR 1098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.